Sign In
Buy RLMD
$6.33
-0.0900 (-1.40%)
At Close: Jun 03, 2026
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
04:30pm, Monday, 09'th Mar 2026
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therap
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
07:05am, Monday, 09'th Mar 2026
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therap
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
07:00am, Monday, 09'th Mar 2026
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC BCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerabi
Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% – Here’s Why
04:48am, Friday, 20'th Feb 2026
Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) traded up 6.9% on Thursday. The company traded as high as $4.47 and last traded at $4.36. Approximately 1,939,623 shares were traded during
Analysts Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) PT at $9.00
01:11am, Sunday, 01'st Feb 2026
Shares of Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) have received a consensus rating of "Hold" from the five ratings firms that are presently covering the company, Marketbeat.com rep
FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD)
02:34am, Monday, 05'th Jan 2026
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the better business? We will compar
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the "Santa Claus"
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD)
02:00am, Thursday, 11'th Dec 2025
BeOne Medicines (NASDAQ: ONC - Get Free Report) and Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two busin
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
07:30am, Wednesday, 03'rd Dec 2025
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustai
Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
07:21pm, Thursday, 13'th Nov 2025
Relmada Therapeutics, Inc. ( RLMD ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Sergio Traversa - CEO & Director Raj Pruthi - Chief Medical Officer of Urology Maged Shenou
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
04:01pm, Thursday, 13'th Nov 2025
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
07:30am, Friday, 07'th Nov 2025
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapi
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
07:09am, Tuesday, 04'th Nov 2025
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapi
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC
